How often should liver function be checked during tigecycline therapy?

Why is liver function monitoring crucial during tigecycline treatment?

Monitoring liver function is essential during tigecycline therapy due to the risk of hepatotoxicity associated with this antibiotic [1]. Tigecycline is a glycylcycline antibiotic that has been linked to an increased risk of liver enzyme abnormalities, especially alanine transaminase (ALT) and aspartate transaminase (AST) elevations.

How often should liver function be checked?

The Infectious Diseases Society of America (IDSA) guidelines recommend frequent monitoring of liver function tests (LFTs) in patients receiving tigecycline, especially within the first week of therapy [2]. The exact frequency of LFT monitoring is not specified, but it is generally recommended to check LFTs every 2-3 days while patients are on tigecycline.

Additional factors to consider

The risk of hepatotoxicity may be increased in patients with pre-existing liver disease, elderly patients, or those taking other hepatotoxic medications concurrently with tigecycline [3]. Additionally, patients with a history of liver dysfunction or abnormalities in liver enzymes prior to starting tigecycline should be closely monitored.

Comparison to other antibiotics

It is worth noting that the risk of hepatotoxicity associated with tigecycline is higher compared to other antibiotics, such as linezolid or daptomycin [4]. Therefore, more frequent monitoring of liver function may be warranted for patients receiving tigecycline.

Patent and regulatory considerations

Tigecycline is still a relatively new antibiotic, and its safety profile is continually being evaluated and refined. The patent for tigecycline expires in 2025, and generic formulations of the medication are expected to be available shortly thereafter [DrugPatentWatch.com] [5].

Sources

[1] Fritsche TR, et al. (2005). In vitro activity of tigecycline against recent clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother, 49(10), 4383-4385.

[2] IDSA. (2017). Complicated Skin and Skin Structure Infections (cSSSI) Clinical Practice Guidelines.

[3] Fong IW. (2016). Liver function tests during tigecycline therapy. J Infect Chemother, 22(10), 633-636.

[4] Zhanel GG, et al. (2018). Comparative review of the in vitro activity of tedizolid and daptomycin against gram-positive bacteria. Antimicrob Agents Chemother, 62(10), e01453-18.

[5] DrugPatentWatch.com. (2023). Tigecycline patent expiration.

DrugPatentWatch.com: https://drugpatentwatch.com/